{"result": {"id": "da3f7edf-06e6-474d-bba1-5f20732f4e86", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>DIURETICS<|>organization<|>Diuretics are used in CKD patients to reduce extracellular volume, with different types recommended based on eGFR levels)\n##\n(\"entity\"<|>Β-RECEPTOR BLOCKERS<|>organization<|>Beta-blockers protect the heart in CKD patients by counteracting sympathetic nervous system overactivation)\n##\n(\"entity\"<|>NSAIDS<|>organization<|>Non-steroidal anti-inflammatory drugs that may cause renal impairment and are cautioned against in CKD patients)\n##\n(\"entity\"<|>THIAZIDE DIURETICS<|>organization<|>Thiazide diuretics are recommended for CKD patients with eGFR ≥30mL/(min·1.73m²))\n##\n(\"entity\"<|>LOOP DIURETICS<|>organization<|>Loop diuretics are recommended for CKD patients with eGFR <30mL/(min·1.73m²))\n##\n(\"relationship\"<|>DIURETICS<|>CKD<|>Diuretics are carefully dosed in CKD patients to avoid volume depletion and renal function decline<|>7)\n##\n(\"relationship\"<|>THIAZIDE DIURETICS<|>CKD<|>Thiazides are first-line diuretics for moderate CKD (eGFR ≥30)<|>8)\n##\n(\"relationship\"<|>LOOP DIURETICS<|>CKD<|>Loop diuretics are preferred for advanced CKD (eGFR <30)<|>8)\n##\n(\"relationship\"<|>Β-RECEPTOR BLOCKERS<|>CKD<|>Beta-blockers provide cardiac protection in CKD patients<|>7)\n##\n(\"relationship\"<|>NSAIDS<|>CKD<|>NSAIDs are cautioned against in CKD due to risk of worsening renal function<|>6)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558758, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 415, "prompt_tokens": 3079, "total_tokens": 3494, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3008}, "prompt_cache_hit_tokens": 3008, "prompt_cache_miss_tokens": 71}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 平 稳 达 标 。对 65~ 79岁 的 老 年  CKD患者 ,可遵循上述降压启动时机及血压控制 目  标 。对高 龄 老 年(≥80岁) CKD 患 者 , 血 压 ≥150/ 90mmHg时 可 启 动 降 压 治 疗 , 血 压 控 制 目 标 为 <  150/90mmHg,如能耐受 , 可 考 虑 将 血 压 控 制 为 <  140/90mmHg[108,589-590] 。\n　8.6.2  降压药应用原则   常用降压药都可用于 CKD 患者降压治疗 。ACEI/ARB不但具有降压作用 ,还能 降低蛋白尿、延缓肾功能的减退 ,改善 CKD患者的预 后 。对于有蛋白尿的 CKD合并高血压患者 ,不论是 否合并糖尿病 , 首选治疗药物应包括一种 ACEI或 ARB。ACEI或 ARB可单独或联合其他降压药应用 , 但不建议两药联合应用 。用药后 2~4周监测血肌酐 ,\n\n\n　较基础值升高>30%时 ,需查找原因(如容量不足、双 侧肾动脉狭窄、合用非甾体抗炎药等) ,必要时减量或 停药[591-592] 。 同时注意监测血钾水平 , 必要时联合降 钾治疗(如纠正酸中毒、利尿、使用肠道钾结合剂等) , 使患者能继续接受 ACEI/ARB治疗 。二氢吡啶类和 非二氢吡啶类 CCB主要依赖其降压作用发挥肾脏保 护功能 。利尿剂通过减少细胞外容量发挥作用 ,应用 时注意避免利尿过度导致血容量不足 ,出现低血压或肾 小球滤过率下降 。在 eGFR≥30mL/(min · 1.73 m2 )  时可选择噻嗪类利尿剂;eGFR<30mL/(min ·1.73m2) 时应用袢利尿剂 。MRA有降压、降低尿蛋白的作用 , 但少数患者 ,尤其是肾功能下降的患者可引起高钾血 症 ,用药后应注意监测 。新型非甾体类 MRA在合并 糖尿病的 CKD患者中显示了心肾获益[399] 。β受体阻 滞剂对抗交感神经系统的过度激活而发挥降压作用 , 对 CKD患者心脏具有保护作用 。研究显示新型降压 药 ARNI在 CKD患者中也具有良好的降压效果 ,并 可改善尿蛋白[593] 。来自心力衰竭研究中合并 CKD 的亚组分析显示 ,ARNI可显著减少这些患者严重肾 脏不 良 事 件 并 延 缓 肾 功 能 下 降[594] 。应 注 意 的 是 , ARNI中含有 ARB的成分 ,用药时也需关注肌酐及血 钾的变化 。SGLT2i在已完成的研究中 ,对无论是否 合并 2型糖尿病的 CKD患者均展现出了心肾保护作 用 ,并 在 研 究 中 对 血 压 有 一 定 改 善 作 用[396] 。 如 果 eGFR≥20\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>CKD<|>organization<|>Chronic Kidney Disease (CKD) is a condition affecting kidney function, with specific treatment guidelines for different age groups and severity levels)\n##\n(\"entity\"<|>ACEI/ARB<|>organization<|>Angiotensin-Converting Enzyme Inhibitors (ACEI) and Angiotensin Receptor Blockers (ARB) are medications used to treat hypertension in CKD patients, also reducing proteinuria and slowing kidney function decline)\n##\n(\"entity\"<|>CCB<|>organization<|>Calcium Channel Blockers (CCB) are a class of drugs used for their blood pressure-lowering effects and kidney protection in CKD patients)\n##\n(\"entity\"<|>MRA<|>organization<|>Mineralocorticoid Receptor Antagonists (MRA) are medications that can lower blood pressure and reduce proteinuria, but may cause hyperkalemia in some CKD patients)\n##\n(\"entity\"<|>ARNI<|>organization<|>Angiotensin Receptor-Neprilysin Inhibitors (ARNI) are a newer class of drugs showing benefits in reducing proteinuria and slowing kidney function decline in CKD patients)\n##\n(\"entity\"<|>SGLT2i<|>organization<|>Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) are medications that provide cardiorenal protection in CKD patients, with some blood pressure-lowering effects)\n##\n(\"relationship\"<|>ACEI/ARB<|>CKD<|>ACEI/ARB are recommended as first-line treatment for CKD patients with hypertension and proteinuria<|>9)\n##\n(\"relationship\"<|>CCB<|>CKD<|>CCB are used in CKD patients primarily for their blood pressure-lowering effects and kidney protection<|>7)\n##\n(\"relationship\"<|>MRA<|>CKD<|>MRA can be used in CKD patients but require careful monitoring due to risk of hyperkalemia<|>6)\n##\n(\"relationship\"<|>ARNI<|>CKD<|>ARNI have shown benefits in reducing proteinuria and slowing kidney function decline in CKD patients<|>8)\n##\n(\"relationship\"<|>SGLT2i<|>CKD<|>SGLT2i provide cardiorenal protection in CKD patients regardless of diabetes status<|>8)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_0fa5aa051bc9d70774980db7540f2f6c576f524eda9db27e834b46e46551099c_v2"}